Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Potential role for HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers.

Hua S, Lécuroux C, Sáez-Cirión A, Pancino G, Girault I, Versmisse P, Boufassa F, Taulera O, Sinet M, Lambotte O, Venet A.

PLoS One. 2014 Jul 7;9(7):e101920. doi: 10.1371/journal.pone.0101920. eCollection 2014.

2.

Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers.

Lécuroux C, Sáez-Cirión A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoël V, Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A.

J Virol. 2014 Jan;88(1):176-87. doi: 10.1128/JVI.02098-13. Epub 2013 Oct 16.

3.

Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection.

Liovat AS, Rey-Cuillé MA, Lécuroux C, Jacquelin B, Girault I, Petitjean G, Zitoun Y, Venet A, Barré-Sinoussi F, Lebon P, Meyer L, Sinet M, Müller-Trutwin M.

PLoS One. 2012;7(10):e46143. doi: 10.1371/journal.pone.0046143. Epub 2012 Oct 2.

4.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544
5.

Early and long-lasting alteration of effector CD45RA(-)Foxp3(high) regulatory T-cell homeostasis during HIV infection.

Simonetta F, Lecuroux C, Girault I, Goujard C, Sinet M, Lambotte O, Venet A, Bourgeois C.

J Infect Dis. 2012 May 15;205(10):1510-9. doi: 10.1093/infdis/jis235. Epub 2012 Mar 28.

6.

Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established?

Goujard C, Chaix ML, Lambotte O, Deveau C, Sinet M, Guergnon J, Courgnaud V, Rouzioux C, Delfraissy JF, Venet A, Meyer L; Agence Nationale de Recherche sur le Sida PRIMO Study Group.

Clin Infect Dis. 2009 Sep 15;49(6):982-6. doi: 10.1086/605504.

PMID:
19681706
7.

Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells.

Lécuroux C, Girault I, Boutboul F, Urrutia A, Goujard C, Meyer L, Lambotte O, Chaix ML, Martinez V, Autran B, Sinet M, Venet A; ANRS PRIMO Cohort, ANRS HIC Study Group; ANRS ALT Cohort; ANRS HIC Study Group.

AIDS. 2009 Aug 24;23(13):1649-58. doi: 10.1097/QAD.0b013e32832e6634.

PMID:
19617814
8.

Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses.

Sáez-Cirión A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fènoël V, Rouzioux C, Delfraissy JF, Barré-Sinoussi F, Lambotte O, Venet A, Pancino G; ANRS EP36 HIV Controllers Study Group.

J Immunol. 2009 Jun 15;182(12):7828-37. doi: 10.4049/jimmunol.0803928.

9.

Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection.

Lécuroux C, Girault I, Urrutia A, Doisne JM, Deveau C, Goujard C, Meyer L, Sinet M, Venet A.

Blood. 2009 Apr 2;113(14):3209-17. doi: 10.1182/blood-2008-07-167601. Epub 2008 Dec 19.

10.

Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts).

Seng R, Goujard C, Desquilbet L, Sinet M, Rouzioux C, Deveau C, Boufassa F, Delfraissy JF, Meyer L, Venet A; ANRS PRIMO and SEROCO Study Groups.

J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):251-8. doi: 10.1097/QAI.0b013e318189a739.

PMID:
18845951
11.

HIV controllers: how do they tame the virus?

Sáez-Cirión A, Pancino G, Sinet M, Venet A, Lambotte O; ANRS EP36 HIV CONTROLLERS study group.

Trends Immunol. 2007 Dec;28(12):532-40. Epub 2007 Nov 5. Review.

PMID:
17981085
12.

Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.

Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle JH, Urrutia A, Scott-Algara D, Boufassa F, Delfraissy JF, Thèze J, Venet A, Chakrabarti LA.

J Virol. 2007 Dec;81(24):13904-15. Epub 2007 Oct 10.

13.

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.

Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group.

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81. Epub 2007 Apr 11.

14.

Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.

Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, Sinet M, Tartour E, Aboulker JP, Autran B, Venet A; ANRS ELISpot Standardization Group.

Clin Vaccine Immunol. 2006 Jun;13(6):684-97.

15.

CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.

Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P; Agence Nationale de Recherche sur le Sida PRIMO Study Group.

Clin Infect Dis. 2006 Mar 1;42(5):709-15. Epub 2006 Jan 24.

PMID:
16447119
16.

Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection.

Kamga I, Kahi S, Develioglu L, Lichtner M, Marañón C, Deveau C, Meyer L, Goujard C, Lebon P, Sinet M, Hosmalin A.

J Infect Dis. 2005 Jul 15;192(2):303-10. Epub 2005 Jun 15.

PMID:
15962225
17.

Does transient HAART during primary HIV-1 infection lower the virological set-point?

Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, Séréni D, Boufassa F, Delfraissy JF, Meyer L; PRIMO and SEROCO Study Groups.

AIDS. 2004 Dec 3;18(18):2361-9.

PMID:
15622312
18.

Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection.

Pacanowski J, Develioglu L, Kamga I, Sinet M, Desvarieux M, Girard PM, Hosmalin A.

J Infect Dis. 2004 Nov 15;190(10):1889-92. Epub 2004 Oct 18.

PMID:
15499547
19.

CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection.

Doisne JM, Urrutia A, Lacabaratz-Porret C, Goujard C, Meyer L, Chaix ML, Sinet M, Venet A.

J Immunol. 2004 Aug 15;173(4):2410-8.

20.

Presence of HIV-specific CD4+ T-cell responses in HIV-infected subjects with sustained virologic control after highly active antiretroviral therapy.

Lacabaratz-Porret C, Viard JP, Goujard C, Lévy Y, Rodallec A, Deveau C, Venet A, Sinet M.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):594-9.

PMID:
15097302
21.

Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.

Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M.

J Infect Dis. 2003 Mar 1;187(5):748-57. Epub 2003 Feb 18.

PMID:
12599048
22.

Animal models of co-infection.

Derouin F, Lacroix C, Brun-Pascaud M, Chau F, Sinet M, Maslo C, Girard PM.

Clin Microbiol Infect. 1998;4(10):559-562. No abstract available.

23.

Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection.

Pacanowski J, Kahi S, Baillet M, Lebon P, Deveau C, Goujard C, Meyer L, Oksenhendler E, Sinet M, Hosmalin A.

Blood. 2001 Nov 15;98(10):3016-21.

24.

Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy.

Ngo-Giang-Huong N, Deveau C, Da Silva I, Pellegrin I, Venet A, Harzic M, Sinet M, Delfraissy JF, Meyer L, Goujard C, Rouzioux C; Frnech PRIMO Cohort Study Group.

AIDS. 2001 Apr 13;15(6):665-73.

PMID:
11371680
25.

Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.

Levacher M, Bouscarat F, Landman R, Chau F, Damond F, Gaudebout C, Mathez D, Leibowitch J, Saimot AG, Sinet M.

AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1869-75.

PMID:
11118072
26.

Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, Ngo N, Rouzioux C, Guillet JG, Delfraissy JF, Sinet M, Venet A.

J Clin Invest. 1999 Nov;104(10):1431-9.

27.

Prospective study of CD8+ lymphocyte activation in relation to viral load in HIV-infected patients with > or = 400 CD4+ lymphocytes per microliter.

Bouscarat F, Levacher M, Dazza MC, Chau F, Desforges B, Muffat-Joly M, Matheron S, Girard PM, Sinet M.

AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1419-25.

PMID:
10555104
28.
29.

Altered ex vivo balance between CD28+ and CD28- cells within HIV-specific CD8+ T cells of HIV-seropositive patients.

Dalod M, Sinet M, Deschemin JC, Fiorentino S, Venet A, Guillet JG.

Eur J Immunol. 1999 Jan;29(1):38-44.

30.

The Th1 to Th2 shift induced by Schistosoma mansoni does not exacerbate murine aids (MAIDS).

Lacroix C, Akarid K, Chau F, Sinet M, Verola O, Carbon C, Derouin F.

Parasite Immunol. 1998 Oct;20(10):497-501.

31.

Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.

Bouscarat F, Levacher M, Landman R, Muffat-Joly M, Girard PM, Saimot AG, Brun-Vézinet F, Sinet M.

AIDS. 1998 Jul 30;12(11):1267-73.

PMID:
9708405
32.

Cryptococcus neoformans infection in mice previously infected with LP-BM5 MuLV, the agent of murine AIDS (MAIDS).

Lacroix C, Chau F, Carbon C, Sinet M, Derouin F.

Clin Exp Immunol. 1997 Nov;110(2):196-202.

33.

The effect of drugs on the mortality of mice inoculated with Friend leukaemia virus or toxoplasma gondii.

Starec M, Sinet M, Kodym P, Rosina J, Fiserová A, Desforges B, Rouveix B.

Physiol Res. 1997;46(2):107-11.

PMID:
9727501
34.

Competitive reverse transcription-polymerase chain reaction for quantifying murine AIDS virus.

Desforges B, Hatin I, Akarid K, Sinet M.

J Virol Methods. 1996 Dec;62(2):161-8.

PMID:
9002074
35.

Absence of involvement of nitric oxide in LP-BM5-induced immunodeficiency syndrome.

Akarid K, Chenais B, Chau F, Sinet M, Desforges B, Gougerot-Pocidalo MA.

FEMS Immunol Med Microbiol. 1996 Sep;15(2-3):169-76.

PMID:
8880143
36.

Mycobacterium avium complex infection in mice: lack of exacerbation after LP-BM5 murine leukemia virus infection.

Grassi F, Perronne C, Levacher-Clergeot M, Cohen Y, Maslo C, Chau F, Sinet M, Pocidalo JJ.

Infect Immun. 1996 Apr;64(4):1203-7.

37.

Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1.

Bouscarat F, Levacher-Clergeot M, Dazza MC, Strauss KW, Girard PM, Ruggeri C, Sinet M.

AIDS Res Hum Retroviruses. 1996 Jan 1;12(1):17-24.

PMID:
8825614
38.

Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo.

Akarid K, Sinet M, Desforges B, Gougerot-Pocidalo MA.

J Virol. 1995 Nov;69(11):7001-5.

39.

Kinetics of ex-vivo cytokine production by splenocytes during murine acquired immunodeficiency syndrome (MAIDS).

Akarid K, Pocidalo MA, Desforges B, Sinet M.

Eur Cytokine Netw. 1995 May-Jun;6(3):181-5.

PMID:
8589275
40.

High-performance liquid chromatographic assay for 3'-amino-3'-deoxythymidine in plasma, with 9-fluorenyl methyl chloroformate as the derivatization agent.

Nattouf H, Davrinche C, Sinet M, Farinotti R.

J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):365-71.

PMID:
7780589
41.

Effects of morphine on the pathogenesis of murine Friend retrovirus infection.

Veyries ML, Sinet M, Desforges B, Rouveix B.

J Pharmacol Exp Ther. 1995 Feb;272(2):498-504.

PMID:
7853162
42.

Interactions between murine AIDS (MAIDS) and toxoplasmosis in co-infected mice.

Lacroix C, Levacher-Clergeot M, Chau F, Sumuyen MH, Sinet M, Pocidalo JJ, Derouin F.

Clin Exp Immunol. 1994 Nov;98(2):190-5.

43.

[Are immunomodulators capable to improve the activity of nucleoside antiretroviral agents?].

Sinet M, Pocidalo JJ.

Pathol Biol (Paris). 1993 Oct;41(8 Pt 2):794-8. Review. French.

PMID:
8309723
44.

Prognostic value of phenotypic alterations in blood lymphocyte subsets in a murine retrovirus-induced immunodeficiency syndrome (MAIDS).

Chau F, Levacher-Clergeot M, Desforges B, Ricatte L, Sinet M.

Clin Exp Immunol. 1993 Mar;91(3):467-72.

45.

Anti-human immunodeficiency virus effects of zidovudine in combination with double-stranded RNA poly I poly C in T cells and monocytes-macrophages.

Gochi K, Sinet M, Dazza MC, Dameron G, Brun-Vezinet F.

AIDS Res Hum Retroviruses. 1992 Jul;8(7):1215-9.

PMID:
1520535
46.

Characteristics associated with HIV-1 infection in pregnant women in Brazzaville, Congo.

Lallemant M, Lallemant-Le Coeur S, Cheynier D, Nzingoula S, Jourdain G, Sinet M, Dazza MC, Larouzé B.

J Acquir Immune Defic Syndr. 1992;5(3):279-85.

PMID:
1740754
47.

Efficacy of continuous zidovudine infusion at early stages of retroviral infection in mice.

Sinet M, Harcouet L, Desforges B, Colin JN, Farinotti R, Pocidalo JJ.

J Acquir Immune Defic Syndr. 1992;5(6):577-82.

PMID:
1316960
48.

Immune status and survival of opiate- and cocaine-treated mice infected with Friend virus.

Starec M, Rouveix B, Sinet M, Chau F, Desforges B, Pocidalo JJ, Lechat P.

J Pharmacol Exp Ther. 1991 Nov;259(2):745-50.

PMID:
1941622
49.

Factors influencing zidovudine efficacy when administered at early stages of Friend virus infection in mice.

Sinet M, Desforges B, Launay O, Colin JN, Pocidalo JJ.

Antiviral Res. 1991 Sep;16(2):163-71.

PMID:
1799277
50.

Mother-child transmission of HIV-1 and infant survival in Brazzaville, Congo.

Lallemant M, Lallemant-Le-Coeur S, Cheynier D, Nzingoula S, Jourdain G, Sinet M, Dazza MC, Blanche S, Griscelli C, Larouzé B.

AIDS. 1989 Oct;3(10):643-6.

PMID:
2512957

Supplemental Content

Support Center